PVP Ventures Limited has announced the acquisition of a significant stake in 7Med India Pvt Ltd and Epitome Group of Hospitals, marking a strategic expansion into the healthcare sector. The Board has approved the purchase of an initial 41.2 per cent stake, with a clear roadmap to majority ownership within 12 months and an eventual increase to 76 per cent.

The transaction, valued at Rs 1.27 billion, involves a mix of primary and secondary stake purchases. This investment aligns with PVP's ambition to build a new-age global healthcare services platform focused on illness, wellness, and care.

Founded by leading nephrology and urology specialists, 7Med operates 22 dialysis centres—both standalone and within hospitals—across six Indian states. It also runs four super-speciality hospitals with a focus on renal care. The company, headquartered in Delhi NCR, employs over 450 professionals and has conducted over one million dialysis procedures to date.

7Med reported an EBITDA of approximately Rs 100 million for FY25, and with PVP’s infusion, aims to scale this to Rs 500 million over the next four years. Expansion plans include broadening its presence in Tier 2 and Tier 3 cities and significantly upgrading local healthcare infrastructure.

Mr Gaurav Davda, Head of M&A and Strategy at PVP, emphasised that the acquisition marks a pivotal step in creating a trusted healthcare brand network tailored to emerging markets. Dr Vijay Kher, Chairman of Epitome Hospitals, added that the partnership would enhance operational efficiency and accelerate access to quality kidney care across geographies.

PVP Ventures, traditionally rooted in real estate, is now actively diversifying through acquisitions. It has partnered with Brigade Enterprises and Casagrand to monetise legacy real estate assets, expecting over Rs 20 billion in cash flows over the next six years, which will be channelled into its healthcare ambitions.